Recombinant Hemagglutinin and Virus-Like Particle Vaccines for H7N9 Influenza virus

Li, Xiaohui; Pushko, Peter; Tretyakova, Irina

doi:10.4172/2157-7560.1000287

Cited by 7 publications

(1 citation statement)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The vaccine candidates currently under investigation include HA/NA peptide, plasmid-based, baculovirus-insect and mammalian protein expression system, and virus-like particle (VLP) vaccines. [29][30][31][32][33][34][35] Some developed candidate vaccines are moving on to clinical trials. In addition, accurate and prompt diagnostic methods that have high sensitivity and specificity are essential for H7N9 influenza disease control and prevention.…”

Section: Introductionmentioning

confidence: 99%

Virus-induced pathogenesis, vaccine development, and diagnosis of novel H7N9 avian influenza A virus in humans: a systemic literature review

Mrc

et al. 2019

J Int Med Res

View full text Add to dashboard Cite

H7N9 avian influenza virus (AIV) caused human infections in 2013 in China. Phylogenetic analyses indicate that H7N9 AIV is a novel reassortant strain with pandemic potential. We conducted a systemic review regarding virus-induced pathogenesis, vaccine development, and diagnosis of H7N9 AIV infection in humans. We followed PRISMA guidelines and searched PubMed, Web of Science, and Google Scholar to identify relevant articles published between January 2013 and December 2018. Pathogenesis data indicated that H7N9 AIV belongs to low pathogenic avian influenza, which is mostly asymptomatic in avian species; however, H7N9 induces high mortality in humans. Sporadic human infections have recently been reported, caused by highly pathogenic avian influenza viruses detected in poultry. H7N9 AIVs resistant to adamantine and oseltamivir cause severe human infection by rapidly inducing progressive acute community-acquired pneumonia, multiorgan dysfunction, and cytokine dysregulation; however, mechanisms via which the virus induces severe

show abstract

Section: Introductionmentioning

confidence: 99%

Virus-induced pathogenesis, vaccine development, and diagnosis of novel H7N9 avian influenza A virus in humans: a systemic literature review

Mrc

et al. 2019

J Int Med Res

View full text Add to dashboard Cite

show abstract

A protective measles virus-derived vaccine inducing long-lasting immune responses against influenza A virus H7N9

et al. 2023

View full text Add to dashboard Cite

A novel Influenza A virus (subtype H7N9) emerged in spring 2013 and caused considerable mortality in zoonotically infected patients. To be prepared for potential pandemics, broadly effective and safe vaccines are crucial. Recombinant measles virus (MeV) encoding antigens of foreign pathogens constitutes a promising vector platform to generate novel vaccines. To characterize the efficacy of H7N9 antigens in a prototypic vaccine platform technology, we generated MeVs encoding either neuraminidase (N9) or hemagglutinin (H7). Moraten vaccine strain-derived vaccine candidates were rescued; they replicated with efficiency comparable to that of the measles vaccine, robustly expressed H7 and N9, and were genetically stable over 10 passages. Immunization of MeV-susceptible mice triggered the production of antibodies against H7 and N9, including hemagglutination-inhibiting and neutralizing antibodies induced by MVvac2-H7(P) and neuraminidase-inhibiting antibodies by MVvac2-N9(P). Vaccinated mice also developed long-lasting H7- and N9-specific T cells. Both MVvac2-H7(P) and MVvac2-N9(P)-vaccinated mice were protected from lethal H7N9 challenge.

show abstract

Progress in developing virus-like particle influenza vaccines

Quan

Lee

Kim

et al. 2016

Expert Review of Vaccines

View full text Add to dashboard Cite

Summary Recombinant vaccines based on virus-like particles (VLPs) or nanoparticles have been successful in their safety and efficacy in preclinical and clinical studies. The technology of expressing enveloped VLP vaccines has combined with molecular engineering of proteins in membrane-anchor and immunogenic forms mimicking the native conformation of surface proteins on the enveloped viruses. This review summarizes recent developments in influenza VLP vaccines against seasonal, pandemic, and avian influenza viruses from the perspective of use in humans. The immunogenicity and efficacies of influenza VLP vaccine in the homologous and cross-protection were reviewed. Discussions include limitations of current influenza vaccination strategies and future directions to confer broadly cross protective new influenza vaccines as well as vaccination.

show abstract

Recombinant Hemagglutinin and Virus-Like Particle Vaccines for H7N9 Influenza virus

Cited by 7 publications

References 90 publications

Virus-induced pathogenesis, vaccine development, and diagnosis of novel H7N9 avian influenza A virus in humans: a systemic literature review

Virus-induced pathogenesis, vaccine development, and diagnosis of novel H7N9 avian influenza A virus in humans: a systemic literature review

A protective measles virus-derived vaccine inducing long-lasting immune responses against influenza A virus H7N9

Progress in developing virus-like particle influenza vaccines

Contact Info

Product

Resources

About